A Phase 2 interventional study of Evolocumab and Ezetimibe in Hyperlipidemia, sponsored by Amgen. Completed at 58 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 8th largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 2, and was the 2nd registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 411 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one is the 8th largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 2, and was the 2nd registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
Other: Placebo to Evolocumab
Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
Other: Placebo to Evolocumab
Participants received 10 mg ezetimibe orally once a day for 12 weeks.
Drug: Ezetimibe
Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
Biological: Evolocumab
Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered orally once a day
Also known as: Zetia
Administered by subcutaneous injection
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
LDL-C was measured using ultracentrifugation.
Time frame: Baseline and Week 12
Change From Baseline in LDL-C at Week 12
LDL-C was measured using ultracentrifugation.
Time frame: Baseline and Week 12
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12
Time frame: Baseline and Week 12
This study enrolled adults 18 - 75 years with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and \< 190 mg/dL, fasting triglycerides ≤ 400 mg/dL and a National Cholesterol Education Program Adult Treatment Panel III Framingham risk score of 10% or less. First patient enrolled 06 July 2011, last patient enrolled 25 November 2011.
| Milestone | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|---|
| Started | 46 | 45 | 46 | 45 | 46 | 45 | 46 | 46 | 46 |
| Received treatment | 45 | 45 | 45 | 45 | 46 | 45 | 45 | 45 | 45 |
| Completed | 44 | 42 | 45 | 45 | 45 | 44 | 44 | 44 | 44 |
| Not completed | 2 | 3 | 1 | 0 | 1 | 1 | 2 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
LDL-C was measured using ultracentrifugation.
| percent change | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 | -3.71 ± 2.66 | 4.54 ± 2.64 | -14.26 ± 2.60 | -40.98 ± 2.64 | -43.87 ± 2.60 | -50.93 ± 2.66 | -39.02 ± 2.57 | -43.20 ± 2.57 | -47.98 ± 2.58 |
LDL-C was measured using ultracentrifugation.
| mg/dL | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in LDL-C at Week 12 | -3.4 ± 3.9 | 7.3 ± 3.7 | -19.2 ± 3.6 | -55.7 ± 3.7 | -66.0 ± 3.7 | -69.3 ± 3.6 | -53.5 ± 3.6 | -56.7 ± 3.6 | -65.0 ± 3.6 |
| percent change | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12 | -2.89 ± 2.40 | -0.25 ± 2.30 | -15.53 ± 2.36 | -37.95 ± 2.38 | -39.68 ± 2.34 | -48.04 ± 2.40 | -37.94 ± 2.24 | -42.14 ± 2.24 | -47.36 ± 2.25 |
| percent change | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 12 | -0.33 ± 2.28 | 0.19 ± 2.28 | -11.17 ± 2.19 | -32.66 ± 2.26 | -36.20 ± 2.23 | -44.52 ± 2.28 | -33.04 ± 2.21 | -37.73 ± 2.21 | -42.29 ± 2.22 |
| percent change | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12 | -1.21 ± 2.17 | -3.39 ± 2.11 | -16.65 ± 1.99 | -30.07 ± 2.15 | -33.13 ± 2.12 | -38.70 ± 2.17 | -32.07 ± 2.05 | -34.60 ± 2.05 | -39.97 ± 2.06 |
| percent change | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12 | 2.03 ± 2.40 | 0.14 ± 2.46 | -12.35 ± 2.33 | -32.80 ± 2.38 | -38.30 ± 2.35 | -48.13 ± 2.40 | -36.10 ± 2.39 | -40.43 ± 2.39 | -45.33 ± 2.40 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | — | 0/45 (0%) | 10/45 (22.2%) |
| Placebo Q4W | — | 0/45 (0%) | 10/45 (22.2%) |
| Ezetimibe | — | 0/45 (0%) | 14/45 (31.1%) |
| Evolocumab 70 mg Q2W | — | 0/45 (0%) | 11/45 (24.4%) |
| Evolocumab 105 mg Q2W | — | 1/46 (2.2%) | 11/46 (23.9%) |
| Evolocumab 140 mg Q2W | — | 1/45 (2.2%) | 14/45 (31.1%) |
| Evolocumab 280 mg Q4W | — | 0/45 (0%) | 7/45 (15.6%) |
| Evolocumab 350 mg Q4W | — | 1/45 (2.2%) | 11/45 (24.4%) |
| Evolocumab 420 mg Q4W | — | 0/45 (0%) | 9/45 (20%) |
| Event | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/45 | 0/45 | 0/45 | 0/45 | 0/46 | 1/45 | 0/45 | 0/45 | 0/45 |
| Humerus fractureInjury, poisoning and procedural complications | 0/45 | 0/45 | 0/45 | 0/45 | 0/46 | 0/45 | 0/45 | 1/45 | 0/45 |
| IgA nephropathyRenal and urinary disorders | 0/45 | 0/45 | 0/45 | 0/45 | 1/46 | 0/45 | 0/45 | 0/45 | 0/45 |
| Event | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W |
|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/45 | 2/45 | 5/45 | 3/45 | 2/46 | 2/45 | 3/45 | 3/45 | 4/45 |
| NasopharyngitisInfections and infestations | 3/45 | 0/45 | 4/45 | 2/45 | 2/46 | 1/45 | 1/45 | 3/45 | 2/45 |
| Back painMusculoskeletal and connective tissue disorders | 0/45 | 4/45 | 1/45 | 1/45 | 1/46 | 2/45 | 1/45 | 1/45 | 3/45 |
| DiarrhoeaGastrointestinal disorders | 0/45 | 3/45 | 1/45 | 2/45 | 0/46 | 2/45 | 0/45 | 3/45 | 3/45 |
| NauseaGastrointestinal disorders | 0/45 | 1/45 | 0/45 | 0/45 | 0/46 | 3/45 | 1/45 | 0/45 | 1/45 |
| FatigueGeneral disorders | 3/45 | 1/45 | 2/45 | 0/45 | 1/46 | 3/45 | 0/45 | 1/45 | 2/45 |
| HeadacheNervous system disorders | 3/45 | 1/45 | 1/45 | 3/45 | 2/46 | 2/45 | 0/45 | 0/45 | 1/45 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/45 | 1/45 | 1/45 | 3/45 | 1/46 | 2/45 | 1/45 | 0/45 | 0/45 |
| Injection site indurationGeneral disorders | 0/45 | 0/45 | 0/45 | 0/45 | 3/46 | 1/45 | 0/45 | 1/45 | 0/45 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 1/45 | 1/45 | 0/45 | 2/45 | 3/46 | 2/45 | 1/45 | 0/45 | 0/45 |
Full analysis set (all randomized participants who received at least 1 dose of investigational product).
| Age, Continuous(years) | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 52.5 ± 9.8 | 50.7 ± 12.6 | 50.0 ± 12.0 | 50.9 ± 12.9 | 48.3 ± 11.8 | 52.8 ± 11.6 | 49.3 ± 10.3 | 50.9 ± 13.1 | 50.1 ± 12.0 | 50.6 ± 11.8 |
| Sex: Female, Male(Participants) | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 25 | 30 | 26 | 30 | 33 | 36 | 28 | 33 | 26 | 267 |
| Male | 20 | 15 | 19 | 15 | 13 | 9 | 17 | 12 | 19 | 139 |
| Race/Ethnicity, Customized(participants) | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 3 |
| Asian | 2 | 1 | 1 | 3 | 3 | 2 | 1 | 2 | 2 | 17 |
| Black or African American | 8 | 7 | 9 | 7 | 5 | 4 | 8 | 6 | 10 | 64 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| White | 35 | 36 | 35 | 33 | 37 | 39 | 35 | 36 | 33 | 319 |
| Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(participants) | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 6 | 5 | 5 | 5 | 8 | 7 | 5 | 10 | 56 |
| ot Hispanic or Latino | 40 | 39 | 40 | 40 | 41 | 37 | 38 | 40 | 35 | 350 |
| Stratification Factor: LDL-C level(participants) | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| < 130 mg/dL | 15 | 14 | 15 | 14 | 15 | 14 | 15 | 15 | 14 | 131 |
| ≥ 130 mg/dL | 30 | 31 | 30 | 31 | 31 | 31 | 30 | 30 | 31 | 275 |
| LDL-C Concentration(mg/dL) | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 147.0 ± 21.0 | 142.3 ± 24.3 | 144.2 ± 25.8 | 143.1 ± 21.7 | 141.5 ± 22.3 | 139.8 ± 21.1 | 141.1 ± 21.8 | 136.6 ± 20.8 | 138.9 ± 21.9 | 141.6 ± 22.3 |
| Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL) | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 173.8 ± 30.5 | 169.1 ± 27.7 | 170.0 ± 32.0 | 169.0 ± 24.5 | 169.2 ± 24.3 | 163.8 ± 23.7 | 166.3 ± 27.8 | 161.1 ± 26.1 | 167.9 ± 29.6 | 167.8 ± 27.4 |
| Apolipoprotein B Concentration(mg/dL) | Placebo Q2W | Placebo Q4W | Ezetimibe | Evolocumab 70 mg Q2W | Evolocumab 105 mg Q2W | Evolocumab 140 mg Q2W | Evolocumab 280 mg Q4W | Evolocumab 350 mg Q4W | Evolocumab 420 mg Q4W | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 111.7 ± 17.1 | 110.4 ± 17.2 | 109.9 ± 17.7 | 108.7 ± 15.7 | 108.5 ± 15.2 | 107.2 ± 16.3 | 109.2 ± 15.7 | 105.8 ± 15.9 | 110.2 ± 18.4 | 109.1 ± 16.5 |
2 further baseline measures are reported on the registry.
Ran from Jul 2011 to primary completion in Mar 2012, 7 months.
Results were first posted in Oct 2015, 3 years 7 months after primary completion. A results delay was requested in Mar 2013.
Of 30 phase 2 interventional studies under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab